The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy

Refleeve : A Retrospective Study to Evaluate the Prevalence of the Barett's Esophagus by Gastro-osephagal Endoscopy in Morbid Obese Patients Treated by Sleeve Gastrectomy and the Advantage of the Systematic Detection in the Prevention of Esophageal Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03596411

Acronym

Refleeve

Enrollment

100

Registered

2018-07-23

Start date

2018-05-17

Completion date

2024-11-17

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux

Brief summary

Severe Gastroesophageal reflux disease (GERD) leading to a chronic aggression of esophagus mucosa, called Barrett's esophagus is a main complication of Sleeve gastrectomy for morbid obesity. Barrett's esophagus is considered as a early stage of neoplastic transformation to adenocarcinoma. Since this last years, six european bariatric centers have adopted the policy to realize endoscopy before and five years or more after sleeve gastrectomy. Investigators worked out a database comprizing the Endoscopic features and patient characteristics. Refleeve projet aim to analyse the long term follow-up datas of 100 patients, evaluate the prevalence of Barret's esophagus and investigate the advantage of the systemetic detection to prevent esophagus adenocarcinomas.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Inclusion criteria

* Patients who had had SG with a minimum follow-up of 5 years, without signs of Barrett's esophagus before SG; * An upper GI endoscopy before the SG; * An upper GI endoscopy indicating that no Barrett's esophagus was present at the time of the SG; * An upper GI endoscopy done with the scope of searching for the endoscopic anomalies of the Barrett's esophagus according to the international guidelines for the diagnosis of Barrett's esophagus 9. * Endoscopic biopsies according to the international guidelines for the diagnosis of Barrett's esophagus 9.

Exclusion criteria

* SG as a conversional procedure from another bariatric procedure such as the gastric banding; * No upper GI endoscopy before the SG * Barrett's esophagus before the SG; * A second procedure after the SG such as the conversion to Roux-en-Y gastric bypass or duodenal switch; * An upper GI endoscopy done not following the international guidelines for the diagnosis of Barrett's esophagus9.

Design outcomes

Primary

Measure	Time frame	Description
Sleeve gastrectomy	5 years	Gastroesophageal endoscopic features before and five years after sleeve gastrectomy

Secondary

Measure	Time frame	Description
Obesity related comorbidity	5 years	obesity related comorbidity before and five years or more after sleeve gastrectomy

Countries

France

Contacts

PRINCIPAL_INVESTIGATORIANNELLI Antonio, PhD

Chirurgie Digestive, CHU de Nice

Outcome results